|
|
Home > Healthcare > Biotechnology > Genetics & Genomics
Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine
|
| Published Date:
April 2009
Published By:
Decision Resources
Page Count:
29
Order Code:
R55-638
|
|
|
|
Introduction
One of the fastest-growing segments of molecular diagnostics is nucleic acid testing (NAT). NAT is central to
the life sciences industry, to improved healthcare, and to personalized medicine. Tools based on NAT are used to
discover new biomarkers and develop in vitro diagnostics. Companies large and small are recognizing the value
of NAT, and both R&D and dealmaking activity is robust. Find out who the players are and how they are vying
for commercial success.
Get the Answers You Need to Shape Your Strategy
- NAT is a leading molecular diagnostics technology. What are the advantages of NAT over other molecular
diagnostics technologies? Which elements of NAT will drive personalized medicine forward?
- Polymerase chain reaction (PCR) is one of the most common methods in the NAT toolbox used to discover
new biomarkers and develop diagnostics tests. What other methods are commonly used for NAT? Which
of these methods have the most product development activity?
- Roche Diagnostics is the clear leader in molecular diagnostics. How do Roche’s sales fi gures compare with
those of smaller diagnostics players? What does the competition look like within the smaller segments?
How are companies using dealmaking to advance their positions?
- Infectious disease and oncology are the two main therapy areas for use of NAT technologies. What are the
growth trends and growth drivers within these therapy areas? What companies are positioned to tap
the opportunities?
Scope
- Importance of NAT for advancing personalized medicine: Use of and rationale for NAT techniques and
products to support the push for personalized medicine.
- Key mergers and acquisitions (M&As), collaboration, and licensing activities in NAT: Two tables featuring
92 alliances that occurred from November 2007 through December 2008.
- Leading NAT markets: Types of assays and tests within infectious disease and oncology that will
continue to have a strong presence in the NAT market.
- Future trends: Insight into strategic considerations required to drive the NAT market and NAT
companies forward.
|
Similar Products
• Biotechnology Sector
Published Nov 2009 by First Research, Inc.
• Dealmaking and Industry Outlook: Neurological Disease
Published Nov 2009 by Decision Resources
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
• The Human Genome Sequencing Center at Baylor College of Medicine Relies on Quantum's StorNext Software for Data Management
Published Oct 2009 by IDC
• Three Alternative Scenarios Of The Future In Vitro Diagnostics Market 2009-2018
Published Oct 2009 by Venture Planning Group
• Preventive Healthcare Technologies, Products and Markets
Published Oct 2009 by BCC Research
• Transfection Life Science Dashboard™ Series 2
Published Oct 2009 by Percepta Associates, Inc.
• Genealogy Products and Services
Published Oct 2009 by Global Industry Analysts
• Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook
Published Oct 2009 by Business Insights
|
|
|
|
0 items
